Division of Dermatology, University of Toronto, Women's College Hospital, 76 Grenville St, Toronto, ON M5S 1B2, Canada.
J Am Acad Dermatol. 2010 May;62(5):824-30. doi: 10.1016/j.jaad.2009.08.016.
Dermicol-P35 27G and 30G are purified advanced collagen dermal fillers that are effective and well tolerated for cosmetic procedures.
The primary objectives of this study were to: (1) document recovery time and return to daily activities after treatment with Dermicol-P35 27G, 30G, or both; and (2) assess the immediate adverse effects of these products and monitor their time to resolution.
In all, 30 patients were treated with Dermicol-P35 27G, 30G, or both in nasolabial folds, lips, corners of the mouth, vermillion border, marionette lines, or a combination of these and monitored for 7 days. Comfort with resuming daily routine, adverse events, and satisfaction with results were documented by patients in diaries. The clinician assessed aesthetic improvement and rated satisfaction with results.
The majority of patients (63.4%) were very comfortable or comfortable returning to their daily routine immediately postprocedure. Most patients (86.7%) participated in normal work or social events within 2 days of treatment. Adverse events were mild to moderate and were resolved or tolerable by day 7. The clinician assessed that most patients had between 50% and 100% improvement over baseline for all procedures at all time points. Clinician and patients were very satisfied or satisfied with aesthetic results at days 2 and 7 postprocedure.
The limitations of this study were the small number of patients, the assessment of short-term results, and the lack of touch-up injections.
Treatment with Dermicol-P35 27G, 30G, or both allowed for rapid return to daily activities and produced only transient and tolerable adverse events.
Dermicol-P35 27G 和 30G 是经过纯化的先进胶原真皮填充剂,在美容治疗中效果显著且耐受性良好。
本研究的主要目的是:(1)记录使用 Dermicol-P35 27G、30G 或两者联合治疗后的恢复时间和恢复日常活动的时间;(2)评估这些产品的即刻不良反应,并监测其缓解时间。
共有 30 例患者在鼻唇沟、嘴唇、口角、唇红缘、木偶线等部位接受 Dermicol-P35 27G、30G 或两者联合治疗,并进行 7 天监测。患者通过日记记录恢复日常活动的舒适度、不良反应以及对结果的满意度。医生评估美学改善情况并对结果满意度进行评分。
大多数患者(63.4%)在治疗后立即恢复日常活动时非常舒适或舒适。大多数患者(86.7%)在治疗后 2 天内即可参加正常的工作或社交活动。不良反应为轻度至中度,在第 7 天缓解或可耐受。医生评估,所有治疗在所有时间点均有 50%至 100%的基线改善。在治疗后第 2 天和第 7 天,医生和患者对美学效果非常满意或满意。
本研究的局限性在于患者数量较少、评估短期结果以及缺乏补注治疗。
使用 Dermicol-P35 27G、30G 或两者联合治疗可快速恢复日常活动,且仅产生短暂和可耐受的不良反应。